Crux, the first benefits platform partnering with big pharma and employers of all sizes to expand transparent and affordable access to transformative quality-of-life (QoL) medications, announced its public launch with $6.5 million in pre-seed funding from Red Cell Partners, a venture studio that builds rapidly scalable, technology-led companies that are bringing revolutionary advancements to market in critical industries like healthcare..

Crux 是首家与大型制药公司和各规模雇主合作的福利平台，致力于扩大对变革性生活质量（QoL）药物的透明且负担得起的获取。该公司宣布正式推出，并从风险投资工作室 Red Cell Partners 获得 650 万美元的预种子轮融资。Red Cell Partners 致力于打造快速可扩展、技术驱动的公司，为医疗保健等关键行业带来革命性的进步。